ABSTRACT
Objectives The purpose is to analyze the potential association of each antibiotic consumption rate and use ratio with COVID-19 morbidity and mortality, and to investigate the efficacy and safe use of antibiotics against COVID-19.
Design Retrospective statistical analysis study of antibiotic use compared with COVID-19 morbidity and mortality.
Methods Each antibiotic defined daily dose (DDD) per 1000 inhabitants per day as each antibiotic consumption rate was available in the official reports and each antibacterial use ratio data was calculated from them. Coronavirus Disease data were obtained from the WHO Coronavirus Disease Dashboard. The relationships between the sum of DDD, each antibacterial DDD, each antibiotic use ratio, and COVID-19 morbidity and mortality were examined. The statistical correlation was calculated by univariate linear regression analysis and expressed by Pearson’s correlation coefficient.
Results The sum of DDD had no statistical correlation with mortality and morbidity. Cephalosporins were a negative correlation with them. Penicillins had a weak positive correlation with them. Macrolides, quinolones, and sulfonates showed a slightly negative correlation tendency with mortality.
Conclusions Cephalosporins may affect less COVID-19 morbidity and mortality. Penicillins suggest to accelerate them. The combination of cephalosporins with macrolides or quinolones may be a helpful treatment. The difference in antibiotic use between Japan and EU/EEA countries will suggest an explanation for the reduction in morbidity and mortality caused by COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No source of funding was used.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This retrospective study was approved by an institutional Research Ethics Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data generated or analyzed during this study are included in this article.
https://www.ecdc.europa.eu/sites/default/files/documents/Antimicrobial-consumption-EU-EEA.pdf
Abbreviations
- DDD
- Defined Daily Dose
- WHO
- World Health Organization
- COVID-19
- Coronavirus Disease 2019
- HIV
- Human Immunodeficiency Virus
- EBV
- Epstein–Barr virus
- CHIKV
- Chikungunya virus
- SARS-CoV-2
- Severe Acute Respiratory Syndrome Coronavirus-2
- MERS
- Middle East respiratory syndrome
- J01A: Tet
- Tetracyclines
- J01C: Pen
- Penicillins
- J01D: Ceph
- Cephalosporins and other beta-lactams
- J01E: Sul
- Sulfonates and trimethoprim
- J01F: Mac
- Macrolides, lincosamides, and streptogramins
- J01M: Qui
- Quinolones
